I hope that everyone had a nice Meatless Monday. Please watch this short preview of "Eating" by RaveDiet.com, it's pretty convincing. After watching the full video, I doubt you would ever eat meat again.
The last few days here in Mexico have been pretty uneventful and I felt it was a good time for me to take a little break. There were a few new faces today and with them brought new stories to change things up a little. It's amazing thing that the little known secret of Gerson is actually pretty well known. One guy told a story of how his very own father went on the Gerson Therapy after his cancer diagnosis. A number of years have since passed and his father is alive, well and remains cancer free.
I've not yet started on the full detoxification program. There was some concern from the doctors here regarding my previous IL-2 treatment. They consider it chemotherapy. Patients that are pre-treated with chemotherapy are put on a much slower detox regimen so that the stored up toxins are released back into the blood slowly.
After some debate, the Dr and I agree that I will gradually move into a more aggressive detox schedule and that it should start while in Mexico. I would much prefer being under his supervision in case I were to encounter a rough reaction rather than by myself at home. I have decided to stay for the third week.
This week is going to be interesting on another front as well. The joint ECCO 15 – 34Th ESMO Multidisciplinary Congress in Berlin is taking place this week. Announcements from Roche are supposed to be released regarding the efficacy of Plx4032 in phase I clinical trials for treating advanced metastatic melanoma. Ahead of this release was some data which is showing some cause for concern.
The company released a statement that raises question over Avastin's effectiveness. Avastin, also known as Bevacizumab, which is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that have spread to other parts of the body. Avastin is already a blockbuster and a key driver for Roche, with global sales of $5 billion in 2008 as a treatment for colon, lung and breast cancers. A last-minute analysis of the clinical data means the picture has now changed.
Here is more information: http://bit.ly/3VsfPr
I'll let you draw your own conclusions. Apparently more data will be released on Wednesday regarding this recent development.
These large drug companies are making huge profits as they drive the "cancer industry" towards their silver bullet drug which sits at the end of the rainbow. These companies must be held liable for the damages that they bestow unto their test subjects as not only can they not offer a cure, but the quantity and quality of life are greatly impacted.
Phase I Study of Ipilimumab and MGN1703
1 week ago